These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24656555)

  • 1. Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.
    Beasley A; White KO; Cremers S; Westhoff C
    Contraception; 2014 May; 89(5):352-6. PubMed ID: 24656555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased 1-year continuation of DMPA among women randomized to self-administration: results from a randomized controlled trial at Planned Parenthood.
    Kohn JE; Simons HR; Della Badia L; Draper E; Morfesis J; Talmont E; Beasley A; McDonald M; Westhoff CL
    Contraception; 2018 Mar; 97(3):198-204. PubMed ID: 29246818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial.
    Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Dal Santo L; Ngwira B
    Lancet Glob Health; 2018 May; 6(5):e568-e578. PubMed ID: 29526707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
    Upadhyay UD; Zlidar VM; Foster DG
    Contraception; 2016 Oct; 94(4):303-13. PubMed ID: 27326938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Client and provider experiences with self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Malawi.
    Burke HM; Packer C; Buluzi M; Healy E; Ngwira B
    Contraception; 2018 Nov; 98(5):405-410. PubMed ID: 29706227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Women's satisfaction, use, storage and disposal of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) during a randomized trial.
    Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Dal Santo L; Ngwira B
    Contraception; 2018 Nov; 98(5):418-422. PubMed ID: 29758176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of training in effective simulated self-injection of subcutaneous depot medroxyprogesterone acetate: observations from a usability study.
    Kaplan I; Ross D; Hilton F; Morgenstern D; Wolter K
    Contraception; 2016 Oct; 94(4):314-20. PubMed ID: 27241898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Affecting Continued Use of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC): A Secondary Analysis of a 1-Year Randomized Trial in Malawi.
    Burke HM; Chen M; Buluzi M; Fuchs R; Wevill S; Venkatasubramanian L; Santo LD; Ngwira B
    Glob Health Sci Pract; 2019 Mar; 7(1):54-65. PubMed ID: 30894394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial.
    Picardo C; Ferreri S
    Contraception; 2010 Aug; 82(2):160-7. PubMed ID: 20654757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception.
    Cameron ST; Glasier A; Johnstone A
    Contraception; 2012 May; 85(5):458-64. PubMed ID: 22079602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women.
    Williams RL; Hensel DJ; Fortenberry JD
    Contraception; 2013 Sep; 88(3):401-7. PubMed ID: 23294549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuation of subcutaneous or intramuscular injectable contraception when administered by facility-based and community health workers: findings from a prospective cohort study in Burkina Faso and Uganda.
    MacLachlan E; Atuyambe LM; Millogo T; Guiella G; Yaro S; Kasasa S; Bukenya J; Nyabigambo A; Mubiru F; Tumusiime J; Onadja Y; Zan LM; Goeum/Sanon C; Kouanda S; Namagembe A
    Contraception; 2018 Nov; 98(5):423-429. PubMed ID: 30125558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study.
    Cover J; Ba M; Lim J; Drake JK; Daff BM
    Contraception; 2017 Sep; 96(3):203-210. PubMed ID: 28673645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuation of self-injected versus provider-administered contraception in Senegal: a nonrandomized, prospective cohort study.
    Cover J; Ba M; Drake JK; NDiaye MD
    Contraception; 2019 Feb; 99(2):137-141. PubMed ID: 30439358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Young Women's Experiences With Subcutaneous Depot Medroxyprogesterone Acetate: A Secondary Analysis of a One-Year Randomized Trial in Malawi.
    Burke HM; Chen M; Packer C; Fuchs R; Ngwira B
    J Adolesc Health; 2020 Nov; 67(5):700-707. PubMed ID: 32389457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuation of injectable contraception when self-injected vs. administered by a facility-based health worker: a nonrandomized, prospective cohort study in Uganda.
    Cover J; Namagembe A; Tumusiime J; Nsangi D; Lim J; Nakiganda-Busiku D
    Contraception; 2018 Nov; 98(5):383-388. PubMed ID: 29654751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability.
    Prabhakaran S; Sweet A
    Contraception; 2012 May; 85(5):453-7. PubMed ID: 22079605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA).
    Katz M; Newmark RL; Aronstam A; O'Grady N; Strome S; Rafie S; Karlin J
    Contraception; 2020 Dec; 102(6):392-395. PubMed ID: 32931811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Society of Family Planning committee consensus on self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC).
    Kohn JE; Berlan ED; Tang JH; Beasley A
    Contraception; 2022 Aug; 112():11-13. PubMed ID: 35378085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of DMPA-SC continuation among urban Nigerian women: the influence of counseling quality and side effects.
    Liu J; Shen J; Diamond-Smith N
    Contraception; 2018 Nov; 98(5):430-437. PubMed ID: 29733817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.